Nanovesicle‐Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects

• DOI: 10.1002/adma.202106516
• Publication Date: 2021-12-28T14:22:15Z
• Authors: Mungyo Jung; Mikyung Kang; Byung‐Seok Kim; Jihye Hong; Cheesue Kim; Choong‐Hyun Koh; Garam Choi; Yeonseok Chung; Byung‐Soo Kim
• Keywords: CTLA-4; Immune checkpoint; Cancer Immunotherapy

Despite the clinically proven efficacies of immune checkpoint blockades, including anti-cytotoxic T lymphocyte-associated protein 4 antibody (αCTLA-4), low response rate and immune-related adverse events (irAEs) in cancer patients represent major drawbacks therapy. These αCTLA-4 therapy are mainly due to suboptimal activation tumor-specific cytotoxic lymphocytes (CTLs) systemic nonspecific cells. To overcome such drawbacks, is delivered by dendritic cell-derived nanovesicles presenting tumor antigens (DCNV-TAs) that exclusively interact with cells, leading selective CTLs. Compared conventional therapy, treatment αCTLA-4-conjugated DCNV-TAs significantly inhibits growth reduces irAEs syngeneic tumor-bearing mice. This study demonstrates spatiotemporal presentation both enables cells potentiates antitumor efficacy without inducing irAEs.